BioTech Scout

Discover the most promising early-stage companies in life sciences, scouted by BioPharmaTrend. Follow company news and important business events.

back to Directory

ProQR Therapeutics

ProQR Therapeutics logo

Founded
2012
Patents
21
Clinical Trials
7
Publications
47

Technologies

Antisense Oligonucleotides RNA-focused Startups

ProQR Therapeutics is a Leiden, NL based biotech company focused on developments of drugs to treat genetic disorders using ADAR enzymes to edit RNA. Based on a novel proprietary technology we discover and develop drugs to change the lives of patients around the world. Founded by industry icons and based on groundbreaking science we strive to make a meaningful impact.


Posts Mentioning This Company

Antisense Oligonucleotides Make Sense

  
Antisense oligonucleotides (ASOs) are short (about 12 to 25 nucleotides long), synthetic single strands of DNA or RNA that are complementary to a chosen sequence. They can alter RNA and reduce, restore, or modify protein expression. ASOs interact with proteins on the surface of cells and enter the cytoplasm. Then …

Top Companies At The Forefront Of RNA Therapeutics Development

  
Alongside the topic of gene editing technologies that keeps making headlines these days, there is also a wave of breakthroughs in the field of RNA-targeting medicines, primarily falling into the following two categories: antisense oligonucleotides (ASO), and RNA interference (RNAi) technologies. (another promising approach, dealing with editing RNA itself by …

A Race For Better Gene Editing Tech Is On

  
A transformative technology for gene editing - clustered regularly interspaced short palindromic repeats (CRISPR) -- has become ubiquitous, at least in research laboratories, where scientists efficiently adopted CRISPR technology to manipulate genes of interest. Still, applying it for humans is associated with greater risks and faces ethical issues. However, alongside …